Bain Capital Private Equity’s acquisition of DSM Sinochem Pharmaceuticals


Clifford Chance has advised Royal DSM (“DSM”) and Sinochem Group on the disposal of their 50/50 joint venture DSM Sinochem Pharmaceuticals (“DSP”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals to Bain Capital Private Equity, a leading global private investment firm.

With roots that date back to 1869, and a long history of technical innovation, DSP develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. In 2017, the company generated sales of approximately €440 million. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the USA and Mexico, with approximately 2,000 employees.

The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.

The Clifford Chance team that advised DSM and Sinochem was led by Gregory Crookes (picture) and Line Poliquin and included Liesbeth Buiter, Laura Franklin, Evert van der Kaa, Pieter Leefers, Rona Nisar, Willemijn de Wit, Amir Adl Rudbordeh, Carlijn Tenge, Sophie van Marwijk Kooy (Corporate), Michiel Sunderman, Daan Smole (Tax), Serkan Özel (notary), Floris van de Bult, Sara Schermerhorn, Bart Bootsma (Employment), Juliette Luycks, Sanne Blankestijn (L&DR), Alvin Khodabaks, Jaap Tempelman, Andrei Mikes (IT/IP), Angela McEwan, Megan Roberts, Rick Verhagen (FMG), Frans Muller, Celine Vermeulen, Jurre Jurriëns (Antitrust). Other offices that were involved: Roger Leese, Nick Mace, Jan Hobbs (London), Brice Hillen (Brussels), Kimi Liu, Jane Chen (Bejing), María Begoña Barrantes, Jorge Martin-Fernández, Diego Doménech, (Madrid), Charmaine Yeo (Singapore), Jay Liang, Echo Yang (Shanghai), Emma Davies, Thomas Walsh, Angel Yao and Dianna Shao (Hong Kong).

Involved fees earner: Liesbeth Buiter – Clifford Chance; Gregory Crookes – Clifford Chance; Line Poliquin – Clifford Chance; Laura Franklin – Clifford Chance; Evert van der Kaa – Clifford Chance; Pieter Leefers – Clifford Chance; Rona Nisar – Clifford Chance; Willemijn de Wit – Clifford Chance; Amir Adl Rudbordeh – Clifford Chance; Carlijn Tenge – Clifford Chance; Sophie van Marwijk Kooy – Clifford Chance; Serkan Özel – Clifford Chance; Brice Hillen – Clifford Chance; María Begoña Barrantes – Clifford Chance; Jorge Martín-Fernández – Clifford Chance; Charmaine Yeo – Clifford Chance; Jay Liang – Clifford Chance; Emma Davies – Clifford Chance; Angel Yao – Clifford Chance; Michiel Sunderman – Clifford Chance; Daan Smole – Clifford Chance; Nick Mace – Clifford Chance; Jan Hobbs – Clifford Chance; Floris van de Bult – Clifford Chance; Sara Schermerhorn – Clifford Chance; Bart Bootsma – Clifford Chance; Juliette Luycks – Clifford Chance; Sanne Blankestijn – Clifford Chance; Roger Leese – Clifford Chance; Thomas Walsh – Clifford Chance; Dianna Shao – Clifford Chance; Alvin Khodabaks – Clifford Chance; Jaap Tempelman – Clifford Chance; Andrei Mikes – Clifford Chance; Angela McEwan – Clifford Chance; Megan Roberts – Clifford Chance; Rick Verhagen – Clifford Chance; Kimi Liu – Clifford Chance; Frans Muller – Clifford Chance; Celine Vermeulen – Clifford Chance; Jurre Jurriens – Clifford Chance; Diego Doménech – Clifford Chance;

Law Firms: Clifford Chance;

Clients: Sinochem Group; Royal DSM;

Author: Michael Patrini